Citation

  • Authors: Rogowski, K., van Dijk, J., Magiera, M. M., Bosc, C., Deloulme, J. C., Bosson, A., Peris, L., Gold, N. D., Lacroix, B., Grau, M. B., Bec, N., Larroque, C., Desagher, S., Holzer, M., Andrieux, A., Moutin, M. J., Janke, C.
  • Year: 2010
  • Journal: Cell 143 564-78
  • Applications: in vitro / DNA / jetPEI
  • Cell types:
    1. Name: HEK-293
      Description: Human embryonic kidney Fibroblast
      Known as: HEK293, 293
    2. Name: HeLa
      Description: Human cervix epitheloid carcinoma cells
    3. Name: MEF
      Description: Murine embryonic fibroblast cells 
    4. Name: U-2 OS
      Description: Human bone osteosarcoma
      Known as: U2OS

Abstract

Polyglutamylation is a posttranslational modification that generates glutamate side chains on tubulins and other proteins. Although this modification has been shown to be reversible, little is known about the enzymes catalyzing deglutamylation. Here we describe the enzymatic mechanism of protein deglutamylation by members of the cytosolic carboxypeptidase (CCP) family. Three enzymes (CCP1, CCP4, and CCP6) catalyze the shortening of polyglutamate chains and a fourth (CCP5) specifically removes the branching point glutamates. In addition, CCP1, CCP4, and CCP6 also remove gene-encoded glutamates from the carboxyl termini of proteins. Accordingly, we show that these enzymes convert detyrosinated tubulin into Delta2-tubulin and also modify other substrates, including myosin light chain kinase 1. We further analyze Purkinje cell degeneration (pcd) mice that lack functional CCP1 and show that microtubule hyperglutamylation is directly linked to neurodegeneration. Taken together, our results reveal that controlling the length of the polyglutamate side chains on tubulin is critical for neuronal survival.

Go to